BALTIMORE — Lupin announced the launch of its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules in the U.S. market, having received an approval from the United States Food and Drug Administration earlier. Lupin’s budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5
BALTIMORE — Lupin announced that it has received approval for its atorvastatin calcium tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer’s Lipitor Tablets, 10 mg, 20 mg, 40 mg and 80 mg. Lupin’s atorvastatin calcium tablets USP
BALTIMORE — Lupin announced the launch of minocycline hydrochloride extended-release tablets USP 55mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s minocycline hydrochloride ER tablets USP 55mg is a generic version of Medicis Pharmaceutical Corporation’s Solodyn 55 mg. It is indicated to treat only inflammatory lesions of non-nodular
BALTIMORE, Md. — Lupin announced on Tuesday that it has received approval from the United States Food and Drug Administration (FDA) to market a generic version of Alvogen’s Fluoxetine Tablets, 60mg. Fluoxetine is indicated in the treatment of major depressive disorders. Fluoxetine Tablets, 60mg, had annual sales of approximately $42.5m in the U.S.
BALTIMORE — Lupin announced that it has received approval for its clobazam tablets, 10 mg and 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Lundbeck Pharmaceuticals Onfi Tablets, 10 mg and 20 mg. Lupin’s clobazam tablets, 10 mg and 20 mg is the generic version of
MUMBAI and BALTIMORE, Md. — Pharma major Lupin announced the launch of tetrabenazine tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine tablets. It is
MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced the launch of atovaquone oral suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration earlier. Lupin’s atovaquone oral suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline’s Mepron oral suspension 750 mg/5 mL. It is
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH — Pharma major Lupin and Mylan announced that the two companies will partner to commercialize a biosimilar to Enbrel (etanercept). Through the partnership agreement, Mylan will commercialize Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia. Enbrel is a TNF-inhibitor indicated to
BALTIMORE — Lupin announced that it has received final approval for its Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, from the United States Food and Drug Administration to market a generic version of Delcor Asset Corporation’s (Delcor) Mycolog-II Cream. Lupin’s Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1mg/gram, is the generic
BALTIMORE — Lupin announced the appointment of Nicholas (Nick) Hart as president – specialty for its U.S. business. Hart will lead the specialty strategic business unit in the United States and will be responsible for Lupin’s specialty brand business growth strategy, P&L and organization. Hart brings over 25 years of specialty business, strategic and commercial operations experience to
MUMBAI, India — Lupin Ltd. plans to buy Gavis Pharmaceuticals LLC and Novel Laboratories Inc. in an $880 million deal. Lupin said Thursday that the acquisition will boost its scale in the U.S. generic drug market and broadens its pipeline in dermatology, controlled-substance products, and other high-value and niche generics. In addition, Gavis brings a
